NCT04606316 - Surgical Nivolumab And Ipilimumab For Recurrent GBM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions

GlioblastomaGBMGlioblastoma MultiformeGrade IV Astrocytoma

Interventions

DRUG

Nivolumab-Placebo

Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.

DRUG

Nivolumab

Given as intravenous (IV) infusion into a vein.

DRUG

Ipilimumab-Placebo

Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.

DRUG

Ipilimumab

Given as intravenous (IV) infusion into a vein.

PROCEDURE

Surgery

Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.

Trial Locations (4)

Memorial Sloan Kettering Cancer Center, New York

University of California Los Angeles, Los Angeles

Stanford University, Stanford

Dana Farber Cancer Institute, Boston